Was looking at the annual and proxy and a couple of small things caught my attention. I realize (rightfully so) the main valuation comes from M-Enoxaparin and M118 but here are a couple of things related to the generic Copaxone program
1. While I realize the compensation goals are generally on the easy to achieve side (IMO) for a lot of the biotechs I follow anyway. It found the following goal and percent achieved significant. Advancement of our M356 ((Generic Copaxone) Program Value=15% Actual Level of Achievement=130% 2. On page three of the annual report (not the 10-k portion) there is the follow text at the end of the M356 update We made significant progress in this program in 2007 and look forward to substantial advancement in 2008[Bold text is my addition not in the report].
Market Data 
Markets 
AI
